Home
»
Press Room
»
Remicade Market To Reach $2.62Bn By 2030 | CAGR -2.28%

Remicade Market Size To Reach $2.62 Billion By 2030

May 2025 | Report Format: Electronic (PDF)

Remicade Market Growth & Trends

The global remicade market size is anticipated to reach USD 2.62 billion by 2030 and is projected to decline at a CAGR of -2.28% from 2025 to 2030, according to a new report by Grand View Research, Inc. Despite a gradual decline in brand dominance, the Remicade (infliximab) market continues to show sustained demand, driven by the global burden of autoimmune diseases such as Crohn’s disease and rheumatoid arthritis. Remicade has remained a widely prescribed biologic for these conditions. However, the market is undergoing significant change due to the increasing entry and acceptance of biosimilars, supported by evolving regulatory policies and healthcare cost-effective strategies.

The decline in market share is closely tied to the broader availability of biosimilar infliximab options. With patents expiring in key regions, biosimilars have become more accessible, particularly in countries with public healthcare systems seeking cost savings. This shift is encouraging broader patient access to treatment while intensifying price competition, challenging the position of the original product. Still, Remicade’s extensive clinical history and physician familiarity support its use, especially in complex cases.

Opportunities for market growth remain, especially in regions where biologic use is still expanding. In markets across Asia, Latin America, and parts of the Middle East and Africa, improvements in healthcare infrastructure and rising awareness of inflammatory diseases are driving increased demand for both originator biologics and biosimilars. Moreover, ongoing clinical research and new infliximab formulations, including subcutaneous delivery, contribute to the evolving therapeutic landscape.

Pharmaceutical companies involved in the Remicade industry, including Janssen, Celltrion, and Pfizer, are responding to these shifts with strategies such as regional licensing deals, post-approval manufacturing partnerships, and investment in real-world evidence. Biosimilar developers also leverage differentiation tactics, including high-concentration formulations and co-marketing agreements, to strengthen market entry.

key Request a free sample copy or view report summary: Remicade Market Report

Remicade Market Report Highlights

Based on type, the branded segment led the market with the largest revenue share of 52.8% in 2024. This dominance is attributable to strong physician trust, established clinical data, slower biosimilar adoption in certain markets, and patient trust in the brand.
Based on indication, the rheumatoid arthritis segment led the market with the largest revenue share of 20.8% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
Based on distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024, due to their direct access to specialized treatments, strong physician recommendations, and higher patient volumes for complex autoimmune conditions, making them the preferred distribution channel for Remicade (infliximab).
In March 2024, Celltrion announced plans to introduce its original drug, Zymfentra, to the U.S. market. The launch of Zymfentra, a treatment for autoimmune diseases, marks a significant step in Celltrion's strategy to expand its portfolio beyond biosimilars. This move reflects the company's broader strategy to diversify its offerings and leverage its expertise in biologic drug development for new therapeutic areas.